Skip to content
Open in App
GSK plc DRC logo

GSK plc DRC

web2

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture...

Symbol · GSK
Company profile

About

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Agreement to acquire Nuvalent

KEY STEP

GSK announced an agreement on 9 June 2026 to acquire Nuvalent for $10.6 billion, adding late stage precision oncology assets including zidesamtinib and neladalkib and expanding its planned presence in lung cancer.

Roadmap reference

Jideytro receives US FDA approval

KEY STEP

On July 22, 2026, the US FDA approved Jideytro, zidesamtinib, for previously treated ROS1 positive non small cell lung cancer. The medicine came from GSK’s acquisition of Nuvalent and became GSK’s first approved lung cancer medicine.

Roadmap reference

GSK announces expanded 2026 phase III program and savings plan

KEY STEP

On July 28, 2026, GSK said it expected more than 20 phase III trial starts during 2026, up from a previous expectation of 10, while launching a three year program targeting £1.9 billion in annual savings by 2029 to support pipeline investment and profitability.

Roadmap reference

Hibsago receives first global approval in Japan

KEY STEP

On August 24, 2026, Japan approved Hibsago, bepirovirsen, as a functional cure treatment for chronic hepatitis B in the specified eligible population. This was the first global approval for the medicine.

Roadmap reference
People

Company team

VS

Vishal Sikka

Independent Non-Executive Director

Company leadership profile.

WM

Wendy Mira Becker

Independent Non-Executive Director

Company leadership profile.

JR

Jonathan Richard Symonds

Chair

Company leadership profile.

LV

Luke Victor Miels

CEO & Director

Company leadership profile.

JB

Julie Belita Brown

CFO & Executive Director

Company leadership profile.

CA

Charles A. Bancroft

Senior Independent Non-Executive Director

Company leadership profile.

HV

Harold V. Barron

Non-Executive Director

Company leadership profile.

AC

Anne C. Beal

Independent Non-Executive Director

Company leadership profile.

HC

Harry C. Dietz

Independent Non-Executive Director

Company leadership profile.

EM

Elizabeth McKee Anderson

Independent Non-Executive Director

Company leadership profile.

TL

Tsun-Huei Lee

Independent Non-Executive Director

Company leadership profile.

GR

Gavin Robert Screaton

Independent Non-Executive Director

Company leadership profile.

RW

Roy Willem Odilia Jakobs

Independent Non-Executive Director

Company leadership profile.

Expert coverage

1 expert evaluated GSK plc DRC.

Orbitrum research

Experts evaluating GSK plc DRC

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment